Patient Care
Academic expertise in a private clinical setting
We are pioneers, innovators, researchers, and educators. Yale School of Medicine Department of Obstetrics, Gynecology and Reproductive Sciences has been at the forefront of major breakthroughs and meaningful refinements on many aspects of women’s health. Simply put, we are here to care for you with the very latest knowledge and techniques when you need it most and have been ranked #4 nationally by the U.S. News & World Report.
Programs & Specialties
Fact Sheets
Female Infertility
Infertility is the inability to get pregnant after a year of trying, which can result from a variety of factors. Learn about symptoms and treatment.
Read moreHigh-Risk Pregnancy
A high-risk pregnancy is one in which a woman and her fetus face a higher-than-normal chance of experiencing complications. Learn about symptoms and treatment.
Read moreMinimally Invasive Gynecologic Surgery
Minimally invasive gynecologic surgery is a type of gynecologic surgery that involves smaller incisions and shorter recovery time. Learn more about these procedures.
Read moreFetal Therapy
With advancements in non-invasive imaging and surgical techniques, it is now possible to treat many problems in a fetus before birth.
Read moreNews from Yale Medicine
In the News
Clinical Trials
A Historical Cohort, Multicenter Study to Characterize the Management, Clinical Course, and Outcomes of Pregnancies in Women Who Have Experienced a Pregnancy With Early Onset Severe HDFN
AgeANY
GenderANY
Date21 February
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
AgeANY
GenderANY
Date24 April
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
AgeANY
GenderANY
Date20 December
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome
AgeANY
GenderANY
Date20 December